Ameritas Investment Company’s Cytokinetics CYTK Stock Holding History

Ameritas Investment Company’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4	Closed	–	–	1140
2018 Q4	$0	Buy	+4	New	+$29	﹤0.01%	1528

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Ameritas Investment Company's CYTK Position: Q1 2019 in Review

Ameritas Investment Company sold out of Cytokinetics (CYTK) in Q1 2019, closing a stake of 4 shares.

Ameritas Investment Company first reported a position in CYTK in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 138 funds tracked by Wall St. Rank hold CYTK as of Q1 2019.

Ameritas Investment Company reported no remaining Cytokinetics position as of Q1 2019 after selling out during the quarter.
Ameritas Investment Company sold 4 Cytokinetics shares in Q1 2019.
Ameritas Investment Company first reported a position in Cytokinetics in Q4 2018 and held it in 1 quarter.
Ameritas Investment Company's Cytokinetics position peaked at $0 in Q4 2018.
138 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2019.

Based on Ameritas Investment Company's 13F filing for Q1 2019, filed 16 May 2019.